Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer

Introduction: We aimed to determine whether KRAS and BRAF mutant colorectal cancer (CRC) cells exhibit distinct sensitivities to the multi-target angiokinase inhibitor, TKI258 (dovitinib). Materials and methods: We screened 10 CRC cell lines by using receptor tyrosine kinase (RTK) array to identify...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Lee, Choong-Kun, Lee, Myung Eun, Lee, Won Suk, Kim, Jeong Min, Park, Kyu Hyun, Kim, Tae Soo, Lee, Kang Young, Ahn, Joong Bae, Chung, Hyun Cheol, Rha, Sun Young
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4300687/
https://ncbi.nlm.nih.gov/pubmed/25628921
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados